lilly - Search News

News

Lilly, Daily Pill and Weight Loss

CNN International on MSN · 22h

Experimental GLP-1 pill helped people with diabetes lose weight and lower blood sugar, Eli Lilly says

Drugmaker Eli Lilly said Thursday that an experimental pill form of popular GLP-1 medications helped people with type 2 diabetes lose an average of nearly 8% of their body weight after 40 weeks and lowered their A1C levels.

The New York Times · 14h

What to Know About Eli Lilly’s Daily Pill for Weight Loss

Eli Lilly reported promising results from a study of its experimental oral drug that could rival popular injections to treat obesity and diabetes.

Reuters on MSN · 16h

Lilly weight-loss pill works as well as Ozempic, shares surge

Eli Lilly's experimental pill worked as well as blockbuster drug Ozempic to lower weight and blood sugar in a trial of diabetes patients, and the company said it expects to seek regulatory approvals by the end of the year.

UnitedHealth, Eli Lilly, TSMC

Reuters on MSN · 17h

Eli Lilly lifts S&P 500, UnitedHealth plummets

The S&P 500 rose on Thursday, lifted by Eli Lilly and Apple, as investors weighed progress in U.S. trade negotiations with Japan against concerns about the outlook for interest rates. Traders leaned toward optimism following U.

Bloomberg L.P. · 22h

Stock Movers: United Health, Eli Lilly, TSMC

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies making news on Wall Street.

Investopedia on MSN · 19h

Top Stock Movers Now: UnitedHealth, Nvidia, Eli Lilly and More

The major U.S. equities indexes were mixed at midday Thursday, with the Dow Jones Industrial Average down close to 400 points as UnitedHealth Group (UNH) shares plunged. The tech-heavy Nasdaq and the S&P 500 were slightly higher.

3hon MSN

Where Will Eli Lilly Be in 5 Years?

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

18h

Eli Lilly: Cementing Its GLP-1 Empire With Orforglipron's Promising Phase 3 Results

Eli Lilly's oral GLP-1 drug orforglipron showed strong Phase 3 results with 7.9% weight loss and good tolerability, ...

Fierce Biotech1d

Lilly's oral GLP-1 drug delivers Ozempic-like efficacy in phase 3 diabetes trial

Eli Lilly has met its goal of achieving semaglutide-like efficacy with an oral GLP-1 drug. | Eli Lilly has met its goal of ...

19h

Why Eli Lilly Stock Is Soaring Today, While Novo Nordisk and Viking Therapeutics Slide

Lilly shares are up 14.2% in response to the news, while shares of its rivals in the GLP-1 weight loss market, Novo Nordisk ( ...

1d

Eli Lilly's Mounjaro Launch Triggers Weight-Loss Drug Craze In India, Novo Nordisk Seeks To Move Up Wegovy Launch

U.S. pharma giant Eli Lilly And Co (NYSE:LLY) announced the launch of its popular weight loss drug Mounjaro (tirzepatide) in ...

4d

Eli Lilly: Still Great, But Still Too Expensive Even As Earnings Near

Eli Lilly benefits from rising cash flow and a strong pipeline, yet elevated pricing versus peers limits near-term gains. See ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results